This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Salud financiera de hoja de balance de Prometheus Biosciences

Salud financiera controles de criterios 6/6

Prometheus Biosciences has a total shareholder equity of $697.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $758.4M and $60.8M respectively.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$713.67m
Patrimonio	US$697.62m
Total pasivo	US$60.80m
Activos totales	US$758.41m

Actualizaciones recientes sobre salud financiera

We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth

May 17

Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

Dec 03

We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

Aug 19

We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

May 04

Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Nov 16

Recent updates

We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth

May 17

Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

Dec 03

We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

Aug 19

Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M

Aug 11

We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

May 04

Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases

Dec 08

Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Nov 16

Prometheus Biosciences: Precision Medicine For IBD

Sep 22

Análisis de la situación financiera

Pasivos a corto plazo: RXDX's short term assets ($726.4M) exceed its short term liabilities ($19.3M).

Pasivo a largo plazo: RXDX's short term assets ($726.4M) exceed its long term liabilities ($41.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: RXDX is debt free.

Reducción de la deuda: RXDX had no debt 5 years ago.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RXDX has sufficient cash runway for more than 3 years based on its current free cash flow.

Pronóstico de cash runway: RXDX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 48.2% each year

This company has been acquired

Salud financiera de hoja de balance de Prometheus Biosciences

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Recent updates

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Prometheus Biosciences, Inc. (NasdaqGS:RXDX) from a group of shareholders.

Chief Financial Officer exercised options to buy US$16m worth of stock.

Consensus revenue estimates decrease by 12%

We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth

Consensus revenue estimates decrease by 34%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.6% to US$163

President notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$1.2m worth of stock

Consensus revenue estimates fall by 66%

Full year 2022 earnings released: US$3.49 loss per share (vs US$2.88 loss in FY 2021)

Chief Financial Officer exercised options and sold US$578k worth of stock

President notifies of intention to sell stock

Prometheus Biosciences Reports Positive Data on Two of Its Clinical Trials

Prometheus Biosciences Announces Positive Results for Pra023 in Both Artemis-UC Phase 2 and Apollo-Cd Phase 2A Studies Enabling Pathway to Both First-In-Class and Best-In-Class Anti-Tl1a Mab

Price target increased to US$78.45

Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.90 loss per share (vs US$0.70 loss in 3Q 2021)

Chief Medical Officer notifies of intention to sell stock

Prometheus Biosciences, Inc. Receives FDA Clearance of IND Application for Its Second Precision Program, PRA052

Price target increased to US$61.91

We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

Consensus revenue estimates increase by 32%

Price target increased to US$57.73

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M

Prometheus Biosciences, Inc. Unveils Its Corresponding Clinical Candidate, PRA052, an Anti-CD30L Monoclonal Antibody

Chief Medical Officer notifies of intention to sell stock

Prometheus Biosciences, Inc. Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis

Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from Russell 2500 Value Index

Consensus forecasts updated

Prometheus Biosciences Provides Enrollment Update in Apollo-Cd and Artemis-Uc Global Phase 2 Studies

Consensus forecasts updated

Prometheus Biosciences, Inc. Appoints Marla Hochfeld as Senior Vice President of Clinical Development and Clinical Affairs

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

High number of new and inexperienced directors

Chairman of Scientific Advisory Board notifies of intention to sell stock

Prometheus Biosciences, Inc., Annual General Meeting, May 19, 2022

Prometheus Biosciences, Inc. Initiates Third Phase 2 Study of Pra023 for Systemic Sclerosis-Associated Interstitial Lung Disease

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Medical Officer notifies of intention to sell stock

Chairman of Scientific Advisory Board notifies of intention to sell stock

Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases

Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Third quarter 2021 earnings released: US$0.70 loss per share

Prometheus Biosciences: Precision Medicine For IBD

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Prometheus Biosciences, Inc. Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-To-Severe Crohn’s Disease

Prometheus Biosciences, Inc. Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-To-Severe Ulcerative Colitis

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera